Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | HTR1A | P08908 | 3/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | GRK2 | P25098 | 2/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.65 |
| ▸ | MPO | P05164 | 1/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.65 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30589885 | 1.00 | L3MBTL1 (0.70) | L3MBTL1CYP3A4HTR1ATP53CYP1A2 | |
| SCHEMBL19236199 | 1.00 | L3MBTL1 (0.70) | L3MBTL1CYP3A4HTR1ATP53CYP1A2 | |
| SCHEMBL9526894 | 1.00 | L3MBTL1 (0.70) | L3MBTL1CYP3A4HTR1ATP53CYP1A2 | |
| SCHEMBL3073046 | 0.92 | L3MBTL1 (0.61) | L3MBTL1CYP3A4HTR1ATP53CYP1A2 | |
| SCHEMBL12538358 | 0.92 | L3MBTL1 (0.61) | L3MBTL1CYP3A4HTR1ATP53CYP1A2 | |
| SCHEMBL8601438 | 0.91 | L3MBTL1 (0.58) | L3MBTL1CYP3A4HTR1ATP53CYP1A2 | |
| SCHEMBL8601442 | 0.91 | L3MBTL1 (0.58) | L3MBTL1CYP3A4HTR1ATP53CYP1A2 | |
| SCHEMBL7966834 | 0.90 | L3MBTL1 (0.58) | L3MBTL1CYP3A4HTR1ATP53CYP1A2 | |
| SCHEMBL5083142 | 0.88 | L3MBTL1 (0.66) | L3MBTL1CYP3A4HTR1ATP53CYP1A2 | |
| SCHEMBL5083143 | 0.88 | L3MBTL1 (0.66) | L3MBTL1CYP3A4HTR1ATP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| EP-2655314-B1 | MULTI-API LOADING PRODRUGS | ALKERMES PHARMA IRELAND LTD (IE) | 2018-02-07 | — | — | EP | disclosed |
| US-20160024011-A1 | Multi-API Loading Prodrugs | ALKERMES PHARMA IRELAND LTD (IE) | 2016-01-28 | — | — | US | disclosed |
| US-20150210712-A1 | Prodrugs of Secondary Amine Compounds | ALKERMES PHARMA IRELAND LTD (IE) | 2015-07-30 | — | — | US | disclosed |
| US-8969337-B2 | Prodrugs of secondary amine compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-03-03 | — | — | US | disclosed |
| US-20130184265-A1 | Prodrugs of Secondary Amine Compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2013-07-18 | — | — | US | disclosed |
| US-20120202823-A1 | Multi-API Loading Prodrugs | ALKERMES, INC. | 2012-08-09 | — | — | US | disclosed |
| WO-2007034270-A2 | IMPROVED PROCESS FOR THE PREPARATION OF (-) TRANS-N-METHYL PAROXETINE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2007-03-29 | — | — | WO | disclosed |
| WO-2001002357-A2 | PROCESS FOR THE SYNTHESIS OF 4-(4'-FLUOROPHENYL)-PIPERIDINES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024011-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | L3MBTL1 3008/4885CYP3A4 69/4885HTR1A 2901/4885 |
| US-20150210712-A1 | Prodrugs of Secondary Amine Compounds | HNMT, MAOB, UGT1A1 | L3MBTL1 3572/4885CYP3A4 82/4885HTR1A 230/4885 |
| US-20130184265-A1 | Prodrugs of Secondary Amine Compounds | HNMT, MAOB, UGT1A1 | L3MBTL1 3572/4885CYP3A4 82/4885HTR1A 230/4885 |
| US-20120202823-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | L3MBTL1 3008/4885CYP3A4 69/4885HTR1A 2901/4885 |
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | AADAC, PAICS, ABCG2 | L3MBTL1 3008/4885CYP3A4 69/4885HTR1A 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.